AZD5363_1143532-39-1_DataSheet_MedChemExpress

P d t D t Sh t Product Name:

AZD5363CAS No.:

1143532-39-1Cat. No.:

HY-15431

Product Data Sheet

MWt:

428.92Formula:

C21H25ClN6O2Purity :>98%

Solubility:DMSO 86 mg/mL Water <1

mg/mL Ethanol <1

mg/mL Mechanisms:

Biological Activity:

AZD5363, a novel pyrrolopyrimidine-derived compound, inhibits all AKT isoforms (IC50 <10 nM).

Pathways:PI3K/Akt/mTOR; Target:Akt mg/mL Ethanol <1 mg/mL

y y ()

IC50 Value: <10 nM(Akt1/2/3)

Target: pan-Akt AZD5363 has potential to treat a range of solid and hematologic tumors as monotherapy or a combinatorial agent, and has potential for personalized medicine based on the genetic status of

PIK3CA, PTEN, and RAS.in vitro: AZD5363, a novel pyrrolopyrimidine-derived compound, inhibited all AKT isoforms with a potency of 10 nmol/L or less and inhibited phosphorylation of AKT substrates in cells with a potency of approximately 0.3 to 0.8 μmol/L. AZD5363 monotherapy inhibited the proliferation of 41 of 182lid d h t l i t ll li ith t f 3l/L l [1]References:

[1]. Davies BR, Greenwood H, Dudley P, Preclinical pharmacology of AZD5363, an inhibitor of AKT:pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background Mol Cancer Ther 2012Apr;11(4):8387 solid and hematologic tumor cell lines with a potency of 3

μmol/L or less[1]. in vivo: Oral dosing of AZD5363 to nude mice caused dose- and time-dependent reduction of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts (PRAS4...

background. Mol Cancer Ther. 2012 Apr;11(4):83-87.

Caution: Not fully tested. For research purposes only

Medchemexpress LLC

https://www.360docs.net/doc/f68781475.html,

18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A

E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m